Hair-growing or hair-fostering agent based on keratin fine particles

WO2023238416A8PCT designated stage expired Publication Date: 2024-12-05MYQTECH INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2022/023554
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2022-06-07
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current hair growth agents like minoxidil, finasteride, and dutasteride have adverse side effects such as blood pressure drops and liver dysfunction, and existing keratin-based hair growth methods are invasive and painful, necessitating a non-toxic, painless, and effective hair growth solution.

Method used

A hair growth agent containing keratin microparticles with a particle size of 0.01 to 100 μm, which can be applied topically in the form of an aqueous solution or hydrogel, promoting hair growth with minimal side effects by enhancing blood circulation and cell viability.

Benefits of technology

The keratin microparticle-based hair growth agent demonstrates higher efficacy and safety compared to traditional keratin dispersions, promoting hair growth without significant toxicity or side effects, as shown by gene expression analysis and animal studies, and can be used in both cosmetic and pharmaceutical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
Patent Text Reader

Abstract

The present invention provides a hair-growing or hair-fostering agent which exhibits a high hair-growing or hair-fostering effect but has no or few side effects. Specifically, provided is a hair-growing or hair-fostering agent containing keratin fine particles as a hair-growing or hair-fostering active ingredient.
Need to check novelty before this filing date? Find Prior Art

Description

Hair growth or hair restoration agent based on keratin microparticles

[0001] The present invention relates to a hair growth or hair restoration agent containing keratin microparticles. The present invention also relates to a cosmetic or pharmaceutical composition containing the hair growth or hair restoration agent.

[0002] Minoxidil, finasteride, and dutasteride are known as representative chemicals that promote hair growth and regrowth. Minoxidil has the effect of dilating blood vessels, and its application promotes blood circulation in the capillaries under the scalp, supplying more nutrients to hair root cells, resulting in hair growth and regrowth effects. However, vascular dilation can cause a drop in blood pressure, adversely affecting the heart and other organs, and in some cases, can lead to critical and even fatal outcomes. Finasteride and dutasteride have been observed to prevent hair loss and promote hair growth by inhibiting the hair loss caused by dihydrotestosterone (DHT), but liver dysfunction has been reported as a serious side effect. Meanwhile, keratin is a protein that is the main component of the hair, claws, feathers, scales, hooves, wool, and horns of animals such as birds, mammals, and reptiles. Because keratin is non-toxic, biodegradable, and exhibits excellent cell viability and good biocompatibility with living cells, research and applications related to the use of keratin are typically related to the fields of pharmaceuticals, medicines, cosmetics, food, agriculture, and biotechnology. Applications of keratin include not only drug delivery but also cell adhesion, cell proliferation, tissue scaffolding, tissue regeneration, cell growth, wound healing, trauma, bioactive surfaces, and medical implant devices (e.g., Non-Patent Documents 1 and 2). Thus, keratin can be formed into multiple shapes, including porous foams, sponges, mats, films, sheets, gels, microfibers, microparticles, nanoparticles, and bulk materials (e.g., Non-Patent Document 2).

[0003] A. Aluigi, et al. , Int. J. Biol. Macromol. , 2007, 41, 266-273K. Katoh et al. , Biomaterials, 2004, 25, 2265-2272 Seong Yeong An, et al. , Research Square, archive, https: / / www. researchsquare. com / article / rs-101358 / v1S. Hu et al. , Sci Adv. 2020, 6 (30): eaba1685

[0004] Regarding the various effects of keratin, it has been reported that subcutaneous injection of keratin itself has a hair growth and restoration effect (Non-Patent Document 3). Furthermore, it has been reported that incorporating keratin into 3D spheroids of dermal papilla cells produces a hair growth effect (Non-Patent Document 4). However, since both effects are highly invasive due to the pain caused by subcutaneous injection, there has been a demand for a technology that can induce hair growth and restoration using keratin through a painless, non-invasive method such as smearing. Furthermore, while various hair growth and restoration agents exist, there remains a demand for the development of a hair growth and restoration agent that exhibits high hair growth and restoration effects but is free of or has minimal toxicity and side effects.

[0005] The present inventors discovered that keratin microparticles exhibit a higher hair growth and restoration effect than ordinary keratin aqueous dispersions when applied, and discovered that keratin microparticles, which are non-toxic to the human body, can be applied to hair growth and restoration, skin care, and health care, leading to the completion of the present invention. For example, the present invention encompasses the following embodiments: [1] A hair growth or restoration agent containing keratin microparticles as a hair growth or restoration active ingredient. [2] The hair growth or restoration agent according to [1], wherein the keratin microparticles have a particle size of 0.01 to 100 μm. [3] The hair growth or restoration agent according to [1] or [2], wherein the keratin microparticles are in the form of an aqueous solution, aqueous dispersion, or hydrogel. [4] The hair growth or restoration agent according to any one of [1] to [3], wherein the keratin comprises human keratin, keratin derived from wool, or partially sulfonated or ionized water-soluble keratin. [5] A cosmetic composition comprising the hair growth or hair restoration agent according to any one of [1] to [4] and a cosmetically acceptable excipient. [6] A pharmaceutical composition comprising the hair growth or hair restoration agent according to any one of [1] to [4] and a pharmaceutically acceptable excipient. [7] The pharmaceutical composition according to [6], which is an external preparation for skin. [8] A method for growing or restoring hair in a subject, comprising applying the hair growth or hair restoration agent or keratin microparticles according to any one of [1] to [4] to the subject. [9] A method for treating or preventing alopecia in a subject, comprising applying the hair growth or hair restoration agent or keratin microparticles according to any one of [1] to [4] to the subject.

[10] The method according to [8] or [9], wherein applying to the subject comprises applying to the skin of the subject.

[11] The method according to [9], wherein the alopecia includes alopecia areata, male-pattern and female-pattern alopecia, alopecia caused by systemic diseases (chronic thyroiditis, iron deficiency anemia, collagen diseases, etc.), drug-induced alopecia (alopecia caused by anticancer drugs, etc.), etc.

[12] Keratin microparticles for use in hair growth or hair restoration agents.

[13] Keratin microparticles for use in hair growth or hair restoration in a subject.

[0006] The present invention provides a hair growth or hair restoration agent that exhibits a high hair growth and hair restoration effect. The active ingredient, keratin microparticles, are non-toxic to animals, including humans, and are therefore particularly effective as cosmetics and pharmaceuticals. In addition, the keratin microparticles are biodegradable, so they have a low environmental impact.

[0007] Figure 1 is a photograph showing the hair growth effect of keratin microparticles in mice. Figure 2 is a graph of principal component analysis (PCA) and a Venn diagram showing changes in gene expression (up-regulation, down-regulation) following treatment with 1% minoxidil, 1% keratin aqueous dispersion (1% keratin), or 1% keratin microparticle suspension (1% keratin microparticles). Figure 3 is a scatter plot showing changes in gene expression (up-regulation, down-regulation) following treatment with 1% keratin aqueous dispersion (1% keratin) or 1% keratin microparticle suspension (1% keratin microparticles). Figure 4 is a heat map by hierarchical clustering of changes in gene expression (up-regulation, down-regulation) following treatment with 1% keratin aqueous dispersion (1% keratin) or 1% keratin microparticle suspension (1% keratin microparticles). Figure 5 is a graph showing gene ontology (GO) upregulated by treatment with keratin microparticles or keratin powder aqueous dispersion. Figure 6A is a graph showing gene pathways upregulated by treatment with keratin microparticles or keratin powder aqueous dispersion. Figure 6B is a graph showing gene pathways downregulated by treatment with keratin microparticles or keratin powder aqueous dispersion. Figure 7 is a Venn diagram and hierarchical clustering heat map of genes changed upon treatment with 1% keratin aqueous dispersion and 1% keratin microparticle suspension. Figure 8 is a graph showing the fold change in gene expression in each biological process by keratin microparticles. Figure 9A is a graph showing the results of microarray validation (Ctnnb1, Notch1) by RT-PCR. Figure 9B is a graph showing the results of microarray validation (DUX, Cdh11) by RT-PCR. Figure 9C is a graph showing the results of microarray validation (Lnk, K14) by RT-PCR. Figure 10 is a photograph showing the adsorption of a keratin microparticle suspension onto a leather surface after application. Figure 11 is a photograph showing the adsorption of a keratin microparticle suspension onto a leather surface after application.Figure 12 shows photographs of a keratin microparticle suspension dropped onto a glass surface before and after drying: A: keratin microspheres (dry spheres); B: keratin microspheres dispersed in water (swollen spherical gel); C: keratin microspheres dispersed in water dropped onto a glass surface and dried (dry disk-shaped structure).

[0008] The present invention is described in detail below. The present invention relates to a hair growth or hair restoration agent containing keratin microparticles as a hair growth or hair restoration active ingredient. In the present invention, "hair growth" and "hair restoration" refer to promoting the growth or growth of hair (e.g., scalp hair, eyebrows, eyelashes, beard, etc.), increasing hair volume (number, thickness, etc.), reducing or inhibiting hair loss, improving the condition of the hair growth site (e.g., inflammatory conditions, etc.), and the like. In the present invention, "keratin" refers to a protein that is the main component of animal hair, nails, feathers, scales, hooves, wool, and horns. Keratin that can be used in cosmetics or pharmaceuticals may be naturally derived or synthetic. Keratin originally derived from a natural organism or environment may be keratin that has been pretreated, such as purified or extracted, or recombinantly produced based on its sequence information. Furthermore, as long as it has the same function as naturally derived keratin, it may be a variant or homologue thereof, or may be chemically modified. The average molecular weight (number average molecular weight) of keratin is, for example, 100 to 100,000, preferably about 200 to 40,000. In a preferred embodiment, the keratin includes human keratin, keratin derived from wool or feathers, or water-soluble keratin obtained by partially sulfonating or ionizing these keratins. A single type of keratin may be used, or two or more types of keratin may be used in combination. Keratin can be prepared by conventional methods by those skilled in the art, or it can be purchased commercially. In the present invention, keratin is used as fine particles with a particle size on the nanometer to micrometer scale. In the present invention, "fine particles" refer to spherical or nearly spherical particles with a particle size of approximately 0.01 to 500 μm, although they do not necessarily have to maintain a spherical shape as long as they are small. In one embodiment, the particle size of the keratin fine particles is preferably 0.1 to 100 μm, more preferably 1 to 10 μm. In one embodiment, at least 90% of the keratin microparticles have a particle size of 0.05 to 100 μm, preferably 0.1 to 20 μm, and more preferably 1 to 10 μm. The keratin microparticles can be prepared by any method known in the art.For example, a method for preparing microparticles using keratin regenerated from wool (F. Cilurzo, et al., Polym. Adv. Technol., 2013, 24, 1025-1028), a method for preparing keratin microparticles using keratin extracted from human hair (Y. Srisuwan and P. Srihanam, Orient. J. Chem., 2019, 35, 1112-1116), a method for preparing microcapsules based on wool keratin (H. Rajabinejad, et al., Ultrason. Sonochem., 2018, 40, 527-532), and the like can be used. In a preferred embodiment, a keratin solution is supplied to a sprayer, air gun, or airbrush using regulated pressurized gas and sprayed directly into a poor solvent (e.g., ethyl acetate). The keratin mist is precipitated in the poor solvent, and the suspension is then left to settle for 6 to 24 hours. The precipitated keratin microparticles are then recovered. This results in the formation of keratin microparticles in the solution. The formed keratin microparticles are then collected by centrifugation and washed with an appropriate solvent to remove unnecessary reagents. The hair growth or hair restoration agent of the present invention contains keratin microparticles as a hair growth or hair restoration active ingredient. While the keratin microparticles may be used as is, they are preferably dissolved, dispersed, or suspended in a solvent. While the solvent that can be used is not particularly limited, it is preferable to use a solvent acceptable for cosmetics or pharmaceuticals. For example, the keratin microparticles can be dissolved, dispersed, or suspended in a solvent such as water or a salt solution (e.g., physiological saline). Therefore, the keratin microparticles can exist in the form of, for example, an aqueous solution, an aqueous dispersion, or a hydrogel. The hair growth or hair restoration agent of the present invention exhibits a hair growth and / or hair restoration effect, for example, a more rapid and / or more abundant hair growth and / or hair restoration effect compared to the case where no treatment is performed. Preferably, the hair growth or hair restoration agent of the present invention has no or few side effects. Examples of such side effects include inflammation (itchiness, rash, redness, etc.), initial hair loss, sweating, chills, palpitations, dizziness, headache, abdominal pain, liver dysfunction (nausea, loss of appetite, etc.), jaundice, decreased libido, and hirsutism. There are no particular limitations on the subject (subject) on which the hair growth or hair restoration agent of the present invention is used.For example, it can be applied to mammals, such as humans, primates (monkeys, chimpanzees, etc.), livestock animals (cows, horses, pigs, etc.), pets (dogs, cats, etc.), and laboratory animals (mice, rats, monkeys, etc.). For example, animal subjects, particularly humans, having areas where hair growth or hair restoration is desired are preferred. The hair growth or hair restoration agent of the present invention can be used as a composition. For example, a composition can be prepared by mixing keratin microparticles with a suitable carrier or diluting or suspending them in a carrier. Examples of suitable carriers include saline (e.g., physiological saline), lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. The composition may also contain commonly used excipients, surfactants, dispersants, buffers, preservatives, solubilizers, stabilizers, isotonicity agents, etc. Other ingredients or compositions may also be mixed or blended into the keratin microparticles. Examples of other ingredients include, but are not limited to, other known hair growth or hair restoration active ingredients (such as ascorbic acid, ginkgo biloba extract, stemoxydine, minoxidil, finasteride, and dutasteride), as well as ingredients with other effects (such as hair active ingredients, moisturizers, softeners, anti-inflammatory agents, minerals, and amino acids). The content of the hair growth or hair restoration agent (keratin microparticles) in the composition varies depending on the form of the composition, the intended use, and the intended purpose, and can be appropriately determined by those skilled in the art taking these factors into consideration. For example, the composition may contain 0.01% to 50% by weight, preferably 0.05% to 20% by weight, of keratin microparticles. In one embodiment, the hair growth or hair restoration agent (keratin microparticles) of the present invention is blended into a cosmetic product and used as a cosmetic composition. The cosmetic to be blended is not particularly limited as long as it is a cosmetic that is applied to areas where hair growth or hair development is desired (for example, scalp hair, beard, etc.).Examples of such cosmetic compositions include hair care products (such as shampoos, treatments, hair sprays, hair packs, hair liquids, and hair tonics), lotions, emulsions, and creams. The cosmetic composition may contain cosmetically acceptable excipients or carriers, such as bulking agents, binders, humectants, lubricants, surfactants, dispersants, buffers, pH adjusters, preservatives, solubilizers, antiseptics, absorption enhancers, stabilizers, isotonicity agents, and fragrances. The cosmetic composition may also contain other known hair growth or hair restoration active ingredients (such as ascorbic acid, ginkgo biloba extract, stemoxydine, minoxidil, finasteride, and dutasteride), as well as other ingredients (such as hair active ingredients, moisturizers, softeners, anti-inflammatory agents, minerals, and amino acids). Depending on the form, the cosmetic composition can be prepared by a conventional method, such as mixing. In another embodiment, the hair growth or hair restoration agent (keratin microparticles) of the present invention is incorporated into a pharmaceutical product and used as a pharmaceutical composition (e.g., a topical skin preparation). In this specification, the term "drug" also includes quasi-drugs. The dosage form of the pharmaceutical composition can be any appropriate form depending on the subject or purpose of application. Preferably, the pharmaceutical composition is an external preparation for skin, such as an ointment, cream, lotion (liquid), gel, aerosol, or transdermal patch. However, other dosage forms suitable for parenteral administration (e.g., intradermal or subcutaneous administration) may also be used. The pharmaceutical composition may contain pharmaceutically acceptable excipients or carriers, such as fillers, binders, humectants, lubricants, surfactants, dispersants, buffers, pH adjusters, preservatives, solubilizers, antiseptics, absorption enhancers, stabilizers, and tonicity agents. The pharmaceutical composition may also contain other known hair growth or hair restoration active ingredients (e.g., minoxidil, finasteride, dutasteride), as well as other ingredients (e.g., moisturizers, emollients, anti-inflammatory agents, minerals, amino acids, etc.). Depending on the form, the pharmaceutical composition can be prepared by conventional methods, such as mixing, application, or spraying. The pharmaceutical composition can be used, for example, as an external skin preparation for treating or preventing diseases or symptoms in areas where hair growth or hair development is desired.For example, it is used for the treatment or prevention of diseases or symptoms such as alopecia areata, male and female pattern hair loss, alopecia caused by systemic diseases (chronic thyroiditis, iron deficiency anemia, collagen disease, etc.), and drug-induced alopecia (alopecia caused by anticancer drugs, etc.). The amount of the composition to be used, the number of times of use, and the period of use can be appropriately determined depending on the amount of keratin microparticles contained, the amount and condition of the hair of the subject to be used, etc. When applied to the skin, the amount per application is generally 1 μg to 50 mg / cm. 2 The composition can be used approximately once to three times a day, once every two days, once every three days, or once a week for one week to three months, or even one month to a year or more, and if necessary, for several years to several decades. The present invention also relates to a method for promoting hair growth or hair restoration in a subject, comprising applying (e.g., applying to the skin) the hair growth or hair restoration agent (keratin microparticles) of the present invention to the subject. The present invention also relates to a method for treating or preventing alopecia in a subject, comprising applying (e.g., topically applying to the skin, or administering subcutaneously or intradermally, the hair growth or hair restoration agent (keratin microparticles) of the present invention to the subject. Furthermore, by combining keratin microparticles with cells, they can be used, for example, as a material for regenerative medicine. For example, the effects of keratin can be exerted in a subject by applying a keratin microparticle suspension to a 3D spheroid and then administering or transplanting the 3D spheroid to the subject. Alternatively, the hair growth and hair restoration effects of keratin can be exerted by administering cells (e.g., hair matrix cells) together with the keratin microparticles.

[0009] The present invention will be described in more detail below with reference to examples and drawings. However, the following examples are not intended to limit the scope of the present invention. [Example 1] Preparation of Keratin Microparticles Keratin microparticles (also referred to as keratin spherical microparticles) were prepared as follows: 1-2 mL of an aqueous keratin solution (concentration 0.1-2 wt%, partially sulfonated, TCI) was supplied to an ultrasonic mist generator, and the resulting keratin mist was added dropwise to 100 mL of a poor solvent (e.g., EtOAc) filled in a 200 mL beaker. The resulting suspension was left for 6-24 hours to precipitate the resulting keratin microparticles. The precipitated keratin microparticles were recovered by filtration and washed several times with the poor solvent. Finally, the keratin microparticles were dried at 25°C and then further dried in a vacuum oven (40°C, -0.1 MPa) to remove any remaining solvent. [Example 2] Demonstration of the Hair Growth Effect of Keratin Microparticles on Mice In this example, the hair growth effect of keratin microparticles on mice was investigated. The experiment was approved by the University of Tsukuba Animal Experimentation Committee (No. 17-060), and the procedures were carried out in accordance with the "Basic Guidelines for Animal Experiments in Physiology" approved by the Board of Directors of the Physiological Society of Japan. Six-week-old male C57BL / 6 mice (Charles River Japan) were individually housed in cages and allowed to acclimate for one week. Afterward, the mice were randomly assigned to experimental groups (n = 5 per group): 1% minoxidil treatment, 1% keratin treatment, 1% keratin microparticle treatment, and milli-Q water treatment (control). After anesthetizing the mice with isoflurane (Wako Pure Chemical Industries), the telogen-containing hair on the backs of the mice was shaved using a hair clipper to induce anagen. Each mouse was then topically treated daily for 4 weeks with 1% minoxidil (Tokyo Chemical Industry Co., Ltd.), 1% keratin aqueous dispersion (Tokyo Chemical Industry Co., Ltd.), 1% keratin microparticle suspension (keratin microparticles prepared in Example 1 suspended in water), or milli-Q water. The shaved dorsal area was observed and photographed daily from the 14th day after treatment. At the end of the treatment period, the mice were sacrificed by cervical dislocation, and the skin harvested from the treatment area was divided into four sections, washed with phosphate-buffered saline (PBS), and then immediately immersed in liquid nitrogen and kept at -80°C. Hair regrowth in the treatment area was measured using the ImageJ processing program (National Institutes of Health, Bethesda, USA).The results are shown in Figure 1. Mice treated with the keratin aqueous dispersion showed hair growth comparable to that of mice treated with no other agent (control). Meanwhile, mice treated with keratin microparticles showed a hair regrowth phenotype comparable to that of mice treated with minoxidil at approximately the same time (10 days after application), demonstrating hair growth promotion due to accelerated hair growth cycles compared to the control and keratin aqueous dispersion. [Example 3] Demonstration of the hair growth effect of keratin microparticles on mice. In this example, genetic analysis was performed using DNA microarrays on skin cells from mice treated in Example 2. RNA used as a template was extracted from skin tissue collected from the treatment area on the back of the mice in Example 2 using ISOGEN solution (Nippon Gene) according to the manufacturer's instructions. The extracted total RNA was amplified and labeled. The labeled fragmented RNA was then hybridized to Affymetrix mouse array strips (Affymetrix). The GeneChips (Mouse Genome 430 2.0 Array) were washed, stained, and scanned using an Affymetrix GeneAtlas Imaging Station to obtain mRNA expression of various genes from the mouse genome. Gene ontology, biological processes, and fold changes in gene expression (2-fold change, control vs. 1% minoxidil, 1% keratin aqueous dispersion, 1% keratin microparticles) were then analyzed using Transcriptome Analysis Console (TAC) software (version 4.0.1) and the Database for annotation, visualization, and integrated discovery (DAVID) bioinformatics resource 6.8. The mean signal log2 (control vs. 1% minoxidil, 1% keratin aqueous dispersion, 1% keratin microparticles) was subjected to hierarchical clustering using Euclidean distance and average linkage algorithms in TIGR Mev version 3.0.3 software (The Institute for Genomic Research, MD, USA).The results are shown in Figures 2 to 9. The results are expressed as mean ± standard deviation (SD) (n = 2 for each). Statistical analysis was performed using Student's t-test when comparing two sets of values ​​(control vs. 1% minoxidil, 1% keratin aqueous dispersion, 1% keratin microparticles). A P value of ≤ 0.05 was considered significant. ANOVA (p-value (condition pair) < 0.05) was performed to evaluate the significance level between treatment groups in vivo. In Figures 2 to 9, the 1% keratin aqueous dispersion is simply referred to as keratin. Figure 2 shows the genes that were up-regulated (>2) or down-regulated (<-2) by each treatment (1% minoxidil, 1% keratin aqueous dispersion, 1% keratin microparticles) compared to the control, using principal component analysis (PCA), Venn diagrams, and a graph showing differentially expressed genes. The results in Figure 2 show that all treatments showed gene expression that differed from the control. The total number of differentially expressed genes, the number of up-regulated genes, and the number of down-regulated genes are summarized in Table 1 below. The number of expressed genes sufficient for analysis is shown. Next, the changes in gene expression (up-regulation, down-regulation) when treated with 1% keratin aqueous dispersion and 1% keratin microparticle suspension compared to the control were analyzed using scatter plots ( FIG. 3 ) and hierarchical clustering ( FIG. 4 ). Of the total 45,077 genes examined, when treated with 1% keratin aqueous dispersion, 11,018 (89.87%) of the 12,260 genes (27.2%) that met the criteria were up-regulated and 1,242 (10.13%) were down-regulated. When treated with 1% keratin microparticle suspension, 8,403 (89.52%) of the 9,387 genes (20.82%) that met the criteria were up-regulated and 984 (10.48%) were down-regulated. The scatter plot shown in Figure 3 reveals the differential gene expression changes caused by 1% keratin aqueous dispersion and 1% keratin microparticles compared to the control. The hierarchical clustering heat map shown in Figure 4 reveals the differential gene expression patterns caused by keratin aqueous dispersion and keratin microparticles compared to the control. Figure 5 shows the gene ontology (GO) upregulated by treatment with keratin microparticles or keratin aqueous dispersion compared to the control. For example, compared to controls, genes related to epithelial development, cellular response to stress, metabolic processes, cell cycle, homeostatic processes, tissue development, mitochondrial activity, and oxidative phosphorylation were upregulated, and in particular, keratin microparticles contributed to the upregulation of genes related to the cell cycle. In other words, keratin aqueous dispersion and keratin microparticles upregulated gene ontologies for hair growth, epidermal development, and cell adhesion, and the effect was more pronounced in the keratin microparticle treatment group.Figures 6A and 6B show gene pathways that were upregulated (A) or downregulated (B) by treatment with keratin microparticles or keratin aqueous dispersion compared to the control. For example, compared to the control, genes in the hallmark of Myc target, VEGF signaling pathway, and innate immune system pathway were upregulated, while genes in the pathways of neurodegeneration were downregulated. Next, gene expression was compared between treatment with keratin microparticles and keratin aqueous dispersion. Of the 1,148 genes that met the criteria out of a total of 45,077 examined genes, 616 genes were upregulated and 532 genes were downregulated by keratin microparticle application. FIG. 7 shows a Venn diagram and hierarchical clustering heat map of genes that changed when treated with a 1% keratin aqueous dispersion (keratin) and a 1% keratin microparticle suspension (keratin microparticles). FIG. 8 shows the fold change in gene expression in each biological process. For example, the expression of genes involved in the processes of cell adhesion, hair follicle morphogenesis, and muscle contraction regulation was significantly increased. These results indicate that treatment with keratin microparticles increases genes related to hair growth, such as the cell cycle and hair cycle, while decreasing genes related to inflammation and stress, suggesting a mechanism that results in hair growth and hair care without toxicity or side effects. The results of microarray validation by RT-PCR are shown in Figures 9A to 9C. The function of each gene and the expression fold change are summarized in Table 2 below. These results suggest that the mechanism of action of the keratin microparticle treatment group is through targeted activation of cell adhesion molecules, which primarily leads to activation of hair growth-related pathways. As a result, hair growth-related pathways such as Notch, shh, JAK / STAT, and BMP were found to be activated. The expression of all genes was significantly increased compared to the keratin aqueous dispersion treatment group. Furthermore, the expression of genes related to epidermal cell and mesenchymal cell migration was elevated, promoting communication between keratinocytes, melanocytes, and dermal papilla cells and further strengthening the hair growth cycle. By enhancing the differentiation potential of epidermal stem cells and keratinocytes, which are the origin of hair matrix cells, greater effects on epidermal stem cells can be expected. Mesenchymal cells, such as dermal papilla cells, are located in the deepest dermis of the skin, and it is possible that the keratin aqueous dispersion did not reach them because the keratin was not completely dissolved. This is thought to be due to targeting growth factor and keratin genes in the epidermis, which activate hair growth-related genes in the dermal papilla. The activation of Notch pathway-related genes, such as Notch 1, which is known to suppress keratinocyte proliferation and promote differentiation leading to hair follicle development, further supports the above explanation. [Example 4] Application Characteristics of Keratin Microparticle Suspension to Leather Surface In this example, the adsorption and drying state of a keratin microparticle suspension on the leather surface after application was examined. Specifically, a fluorescent dye (Acid Red 52) was added to the keratin microparticles (1% suspension) and the keratin aqueous solution (1% suspension) prepared in Example 2, and each suspension was then applied to the surface of pig leather to confirm adsorption to the leather surface. A 1% aqueous dispersion of keratin powder was also similarly applied to the surface of pig leather to confirm adsorption to the leather surface. The results are shown in Figures 10 and 11. As shown in Figure 10, when an aqueous keratin solution or a 1% aqueous dispersion of keratin powder was applied, the keratin aggregated after drying, whereas when a 1% aqueous dispersion of keratin microparticles was applied, the keratin microparticles were found to be uniformly dispersed over the entire leather surface. The fact that the keratin microparticles were dispersed over the entire surface is also evident from the fluorescence microscope image shown in Figure 11.Furthermore, when a suspension of keratin microparticles was applied to glass and allowed to dry naturally, a disk-like structure covering the surface was observed (Figure 12). As shown in Figure 12, the diameter of the keratin microparticles (dry spheres) was 1-10 μm (A), the diameter of the keratin microparticles dispersed in water (swollen spherical gel) was 10-100 μm (B), and the diameter of the keratin microparticles dispersed in water, when dropped onto glass and dried (dried disk-like structure), was 10-100 μm (C). This indicates that the keratin microparticles swell in water to form a spherical gel and are not completely dissolved. This suggests that keratin forms a three-dimensional network structure in water, which causes properties similar to the hair growth effect of keratin in 3D cells. [Example 5] Application of a Keratin Microparticle Suspension to Human Subjects The effects of topical application of keratin microparticles to human subjects were investigated using the following procedure. The test solution used was the 1% aqueous solution of keratin microparticles prepared in Example 2. (1) Shave both sideburns using an electric shaver and clippers. (2) Apply the 1% aqueous solution of keratin microparticles to an area of ​​approximately 3 x 6 cm, including the right sideburns, using a cotton swab. The application volume was approximately 0.4 mL, twice daily, in the morning (after waking up) and evening (after bathing). As a result of the above test, no adverse reactions such as allergies or rashes were observed after 14 days. It was also confirmed that hair growth extended further downward in the treated area of ​​the right sideburns compared to the untreated left sideburns. All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.

[0010] The present invention provides a hair growth or hair restoration agent that exhibits a high hair growth or hair restoration effect. The present invention can be used in the fields of cosmetic materials, cosmetics, pharmaceuticals, etc.

Claims

1. A hair growth or hair restoration agent containing keratin microparticles as an active ingredient for hair growth or hair restoration.

2. The hair growth or hair care agent according to claim 1, wherein the particle size of the keratin microparticles is 0.01 to 100 μm.

3. The hair growth or hair care agent according to claim 1, wherein the keratin microparticles are in the form of an aqueous solution, an aqueous dispersion, or a hydrogel.

4. The hair growth or hair care agent according to claim 1, wherein the keratin comprises human keratin, keratin derived from wool, or partially sulfonated or ionized water-soluble keratin.

5. A cosmetic composition comprising the hair growth or hair care agent of claim 1 and a cosmetically acceptable excipient.

6. A pharmaceutical composition comprising the hair growth or hair restoration agent of claim 1 and a pharmaceutically acceptable excipient.

7. The pharmaceutical composition according to claim 6, which is an external preparation for skin.